Skip to main content

Tweets

RheumNow Live 2026 Rheumatologists don’t just attend #RheumNowLive — they shape it. Join the conversation that defines our field. 🕓 Early Bird registration open through 12/1 👉 https://t.co/zYYC2350tE #RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity https://t.co/ejOB2WmOiv
Dr. John Cush @RheumNow ( View Tweet )
1 hour 14 minutes ago
25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/4nhACulIw0
Dr. John Cush @RheumNow ( View Tweet )
1 hour 45 minutes ago
Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxn https://t.co/2qa7O2v6fm

Dr. John Cush @RheumNow ( View Tweet )

3 hours 29 minutes ago
Seeking Musculoskeletal Care A report entitled The Burden of Musculoskeletal Diseases in the United States (BMUS) was published by the USBJD with input from rheumatology, orthopedic surgery, physical medicine and rehabilitation regarding musculoskeletal care. https://t.co/KGYHrQYADE
Dr. John Cush @RheumNow ( View Tweet )
4 hours 45 minutes ago
ICYMI: Head-to-Head Clinical Trials https://t.co/LpvqQRP06b https://t.co/YkXYvUuJWx
Dr. John Cush @RheumNow ( View Tweet )
7 hours 45 minutes ago
Retrospective review of 113 AOSD pts, median age 45yrs, ferritin 4626 (IQR 1169–14,239). Advanced Rx (IVIG, IL-1, IL-6) required in 15 (13.3%), NOT predicted by ferritin levels, either measured continuously or by quartiles. Ferritin is not a reliable biomarker in AOSD. https://t.co/pHEPeIf9u2
Dr. John Cush @RheumNow ( View Tweet )
21 hours 45 minutes ago
Lupus Nephritis study of 136 pts followed 121 mos. Median time to wean GC to 7.5 mg/day, 5 mg/day & D/C was 9, 12 & 29 months post-Dx. Predictors of shorter time to D/C= Sustained CR/SLEDAI-2K≤4, membranous LN, & HCQ. Prolonged GC & renal flares increase damage accrual

Dr. John Cush @RheumNow ( View Tweet )

23 hours 15 minutes ago
Review of neonatal Fc receptor (FcRn) blockers, being developed by J&J, argenx & UCB, showing utility in autoimmune dz as they reduce autoantibodies. FcRn inhibitor market may be worth USD 3.3 billion by 2035. Approved for myasthenia gravis & being developed in Sjögren’s, SLE, https://t.co/mBUla87dK5
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Japanese ANSWER cohort (3623 RA pts on bDMARDs or JAKi) included looked at T2T in 118 RA pregnancies. 93% had full-term deliveries; 85% w/ remission or LDA maintained throughout preg. 35/118 cont' bDMARDs during preg & had signif lower DAS28-CRP vs those D/C (n 24) (P = 0.007). https://t.co/uG8m7RzSiU
Dr. John Cush @RheumNow ( View Tweet )
1 day 5 hours ago
Serum IL-1Ra levels are elevated in Lg vessel vasculitis - 21 active, Rx naive LVV pts (13 GCA, 8 TAK), IL-1Ra higher in TAK (465 pg/mL) & GCA (385 pg/mL) vs NLs (170). IL-6 also incr. in LVV, but IL-1β & IFN-γ incr in GCA & ^ IL-17in TAK. IL-1Ra correlate w/ CRP in GCA & https://t.co/TFDpK5DqcJ
Dr. John Cush @RheumNow ( View Tweet )
1 day 6 hours ago
Australian Vaccine study (2019 - 2021) - w/in 12 mos of b/tsDMARD initiation 73% (11,225/15,460) recv influenza vaccination. High-dose Flu vax used in 28% in 60–69 yo, but > 80% older than 70yo. Only 9.7% recv pneumococcal & 2.4% zoster Zostavax or Shingrix) vax w/in 6 months of https://t.co/xoGTWMUi1L
Dr. John Cush @RheumNow ( View Tweet )
1 day 20 hours ago
Metanalysis of 56 articles & 72,677 RA pts w/ a Dz duration of 9.7 yrs looked at biologic persistence. In csDMARD-IR, over 5 yrs TCZ (66%) & golimumab (62%) best. In bDMARD-IR, ABA (45%) & ETN (41%) best. Lower Rx survival predicted by steroids, hi Dz activity, & female https://t.co/tepL0A9Fwb
Dr. John Cush @RheumNow ( View Tweet )
1 day 22 hours ago
×